title: Increased urinary NO2-/NO3- and cyclic guanosine monophosphate levels in patients with Bartter's syndrome: relationship to vascular reactivity.
abstract: Nitric oxide (NO) is a potent endogenous vasodilator and plays a pivotal role in the control of vascular tone by the formation of cyclic guanosine monophosphate (GMP). Patients affected by Bartter's syndrome have lower than normal vascular reactivity with normohypotension and decreased peripheral resistances in spite of biochemical and hormonal abnormalities typical of hypertension, and it is possible that increased production of NO may be involved in maintaining this reduced vascular response and vasodilatation. We have examined this possibility by studying NO2-/NO3- and cyclic GMP urinary excretions to assess NO production in vivo in seven patients affected by Bartter's syndrome compared with seven healthy controls. A group of five patients with hypokalemia other than Bartter syndrome (pseudo-Bartters) was also included in the study to evaluate the effect of hypokalemia on NO production. NO2-/NO3- urinary excretion (0.45 +/- 0.14 v 0.25 +/- 0.04 micromol/micromol urinary creatinine [controls], P < 0.005, v 0.28 +/- 0.05 [pseudo-Bartters], P < 0.01) and cyclic GMP urinary excretion (0.057 +/- 0.028 v 0.022 +/- 0.01 micromol/micromol of urinary creatinine [controls], P < 0.009, v 0.024 +/- 0.004 [pseudo-Bartters], P < 0.02) were increased in patients with Bartter's syndrome in comparison with controls and pseudo-Bartters, and a linear correlation between these two parameters was also present (P < 0.001). We conclude that in Bartter's syndrome the increased NO2-/NO3- and cyclic GMP urinary excretions point to an increased NO synthesis, which could account for the reduced vascular response of the disease, therefore adding its role in determining the vascular hyporeactivity of Bartter's syndrome.
authors.affiliation: Institute of Internal Medicine, Division of Nephrology, University of Padova, Padova, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Caló
authors.forename: A
authors.initials: A
authors.lastname: D'Angelo
authors.forename: S
authors.initials: S
authors.lastname: Cantaro
authors.forename: M C
authors.initials: MC
authors.lastname: Bordin
authors.forename: S
authors.initials: S
authors.lastname: Favaro
authors.forename: A
authors.initials: A
authors.lastname: Antonello
authors.forename: A
authors.initials: A
authors.lastname: Borsatti
mesh_terms: D000293:Adolescent; D000328:Adult; D001477:Bartter Syndrome / Q000503:physiopathology* / Q000652:urine*; D003404:Creatinine / Q000652:urine; D006152:Cyclic GMP / Q000652:urine*; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000503:physiopathology / Q000652:urine; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000652:urine*; D009569:Nitric Oxide / Q000502:physiology; D009573:Nitrites / Q000652:urine*; D014661:Vasoconstriction / Q000502:physiology; D014664:Vasodilation / Q000502:physiology*
chemical_list: D009566:Nitrates; D009573:Nitrites; D009569:Nitric Oxide; D003404:Creatinine; D006152:Cyclic GMP